Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin hydrochloride micelles
- Development stage
- Phase 1
- Lead developer
- Kairuilong
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Doxorubicin hydrochloride micelles is an investigational nanoparticle formulation of the anthracycline chemotherapy agent doxorubicin, developed by Kairuilong (Beijing) Pharmaceutical in collaboration with the Institute of Biophysics of the Chinese Academy of Sciences. The drug utilizes a micellar delivery system designed to encapsulate doxorubicin hydrochloride, which aims to improve the pharmacokinetic profile and biodistribution of the drug. By leveraging the enhanced permeability and retention (EPR) effect, the micellar formulation is intended to increase drug accumulation within tumor tissues while minimizing exposure to healthy tissues, thereby reducing systemic toxicities such as cardiotoxicity and myelosuppression. The active moiety, doxorubicin, exerts its antineoplastic effect by intercalating into DNA and inhibiting topoisomerase II, which prevents DNA replication and induces apoptosis. It is currently in Phase I clinical development in China for the treatment of advanced solid tumors.
- Other names
- doxorubicin hydrochloride micelles for injection盐酸阿霉素胶束
02
Targets
DNATOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)αVβ3 (Integrin αVβ3)ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on doxorubicin hydrochloride micelles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin hydrochloride micelles.